Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 1 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Minghong Zhong currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. All of these actions are assigned to 1 distinct examiner and are located within 1 distinct art unit. This indicates a high degree of centralization, as all current prosecution matters are being handled by the same individual in the same administrative unit.
The busiest examiner for this portfolio is MCLEOD, AFRICA MHAIRIE, who is managing 3 pending office actions. Because there is only 1 distinct examiner involved, MCLEOD, AFRICA MHAIRIE is responsible for all of the company's pending workload in the Biotechnology & Pharmaceuticals sector. This concentration allows the company to develop a consistent relationship and strategy across all 3 of the pending office actions.
The fact that 3 pending office actions are consolidated within 1 distinct art unit suggests that the underlying applications may be closely related. MCLEOD, AFRICA MHAIRIE will have a significant influence on the company's immediate patent outcomes. This profile, featuring 1 distinct examiner and 1 distinct art unit, simplifies the management of the current portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCLEOD, AFRICA MHAIRIE | 3 | 52.8% | +67.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18218659 | LgRNA-directed CRISPR Gene Editing | MCLEOD, AFRICA MHAIRIE | — |
| 17194312 | Chemically Ligated RNAs for CRISPR/Cas9-lgRNA Complexes as Antiviral Therapeutic Agents | MCLEOD, AFRICA MHAIRIE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18218659 | LgRNA-directed CRISPR Gene Editing | MCLEOD, AFRICA MHAIRIE | — |
| 17636857 | Conjugates of Guide RNA-Cas Protein Complex | MCLEOD, AFRICA MHAIRIE | — |
| 17194312 | Chemically Ligated RNAs for CRISPR/Cas9-lgRNA Complexes as Antiviral Therapeutic Agents | MCLEOD, AFRICA MHAIRIE | — |
| Art Unit | Apps |
|---|---|
| 1635 | 3 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18218659 | LgRNA-directed CRISPR Gene Editing | MCLEOD, AFRICA MHAIRIE | 1635 | §102§103§112Other | Non-Final OA | — | Pending | Jul 06, 2023 |
| 17636857 | Conjugates of Guide RNA-Cas Protein Complex | MCLEOD, AFRICA MHAIRIE | 1635 | §103§112DP | Non-Final OA | — | Pending | May 20, 2022 |
| 17194312 | Chemically Ligated RNAs for CRISPR/Cas9-lgRNA Complexes as Antiviral Therapeutic Agents | MCLEOD, AFRICA MHAIRIE | 1635 | §102§103§112Other | Non-Final OA | — | Pending | Mar 08, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMinghong Zhong has 3 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Africa Mhairie Mcleod has the most, with 3 of Minghong Zhong's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
